|
United States patent #10,738,095 granted on 2020-08-11
Australia patent #2016271292 granted 2022-07-28 Canada patent #2988086A1 granted 2023-05-02 European patent #3302527B1 granted 2020-01-08 (nationalized in 5 countries) Japan patent #2017562777A granted 2020-11-18 WE ARE CURRENTLY PURSUING NEW METHOD OF USE IP. Getschman AE, Imai Y, Larsen O, Peterson FC, Wu X, Rosenkilde MM, Hwang ST and Volkman BF, Protein engineering of the chemokine CCL20 prevents psoriasiform dermatitis in an IL-23-dependent murine model (2017) Proc Nat Acad Sci USA 114 12460-12465. Egner JM, Jensen DR, Olp MD, Kennedy NW, Volkman BF, Peterson FC, Smith BC, Hill RB, Development and Validation of a 2D Difference Intensity Analysis for Chemical Library Screening by Protein-Detected NMR (2018) ChemBioChem 19 448-458 Riutta SJ, Larsen O, Getschman AE, Rosenkilde MM, Hwang ST and Volkman BF, Mutational analysis of CCL20 reveals flexibility of N-terminal amino acid composition and length (2018) J Leuk Biol 104 423-434. Lau S, Feitzinger A, Venkiteswaran G, Wang J, Lewellis SW, Koplinski CA, Peterson FC, Volkman BF, Meier-Schellersheim M, Knaut H. A negative-feedback loop maintains optimal chemokine concentrations for directional cell migration (2020) Nature Cell Biology 22 266-273. Wedemeyer MJ, Mahn SA, Getschman AE, Peterson FC, Marchese A, McCorvy JD, and Volkman BF, The chemokine X-factor: structure-function analysis between CC and CXC chemokines at CXCR4 and ACKR3 (2020) J Biol Chem 295 13927-13939. Ren X, Getschman AE, Hwang S, Volkman BF, Klonisch T, Levin D, Zhao M, Santos S, Liu S, Cheng J and Lin F, Investigations on T Cell Transmigration in a Human Skin-on-Chip (SoC) Model (2021) Lab on a Chip 21 1527-1539. Gutjahr JC, Crawford KS, Jensen DR, Naik P, Peterson FC, Samson GPB, Legler DF, Duchene J, Veldkamp CT, Rot A and Volkman BF, Dimeric form of CXCL12 binds to atypical chemokine receptor 1 (2021) Science Signaling 14 (696):eabc9012. Shi Z, Garcia-Melchor E, Wu X, Getschman AE, Nguyen M, Rowland DJ, Wilson M, Sunzini F, Akbar M, Huynh M, Law L, Raychaudhuri S, Volkman BF, Millar NL, and Hwang ST, Targeting the CCR6/CCL20 axis in entheseal and cutaneous inflammation, Arthritis & Rheumatology 73 2271-2281. Kleist AB, Jenjak S, Sente A, Laskowski LJ, Anderson EI, McNally LM, Heukers R, Bobkov V, Peterson FC, Thomas MA, Chevigne A, Smit MJ, McCorvy JD, Babu MM and Volkman BF, Conformational selection guides β-arrestin recruitment at an intrinsically biased G protein-coupled receptor (2022) Science 377 222-228. Elmansi A, Eisa N, Periyasamy-Thandavan S, Kondrikova G, Kondrikov D, Calkins M, Aguilar-Pérez A, Chen J, Johnson M, Shi X, Reitman C, McGee-Lawrence M, Crawford K, Dwinell MB, Volkman BF, Blumer J, Luttrell L, McCorvy J, Hill W, Breaking Bad: DPP4 Truncated CXCL12 Alters CXCR4/ACKR3 Signaling, Osteogenic Cell Differentiation, Migration, and Senescence (2022) ACS Pharmacology & Translational Science 6 22-39. Wu X, Clarke WF, Koplinski CA, Peterson FC, Dwinell MB, Wei G, Chao E, Huynh M, Yamada D, Volkman BF, and Hwang ST, A modified ELISA assay differentiates CCL20 locked dimers from wild-type monomers (2023) J Immunol Methods 515 113453.
XLock Biosciences’ CEO Dr. William Clarke has been awarded a Direct to Phase II SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases in the of $1.99M for his project titled “Targeting the CCR6-CCL20 pathway for treatment of psoriatic joint and entheseal inflammation”.
Group for Research and Assessment in Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 Meeting7/14/2023
 Kyorin University Hospital EVENT DATE: 7/14/2023
Dermatologists and rheumatologists often collaborate on the most complicated of autoimmune disease, including psoriasis and psoriatic arthritis. The Group for Research and Assessment in Psoriasis and Psoriatic Arthritis (GRAPPA), composed of both rheumatologists and dermatologists interested in curing psoriatic disease, held its annual meeting in Dublin Ireland from July 14-16, 2023. Dr. Sam Hwang was invited to give a plenary lecture on "Targeting psoriatic skin and joint disease through the chemokine receptor, CCR6", in which he outlined the rationale for blocking CCR6 with the CCL20 locked dimer as a novel potential treatment for these diseases which affects up to 3 percent of Americans.  EVENT DATE: 6/13/2023
Invited speaker, Gordon Research Conference on Molecular Pharmacology, Les Diablerets, Switzerland, “Conformational Selection in ACKR3 Activation and Inhibition by Ligands Large and Small”. At the ENC conference in California and at the Molecular Pharmacology GRC in Switzerland a few months later, Dr. Volkman presented findings from a recent NMR study carried out in his MCW research lab on the conformational regulation of the atypical chemokine receptor 3 (ACKR3). These results, which were published last year in Science, demonstrate that recruitment of beta arrestin involves the dampening of internal motions to stabilize the active state of the receptor.
|
XLock Biosciences
662 South 94th Place
West Allis, WI 53214
A Milwaukee Biopharmaceutical Company
662 South 94th Place
West Allis, WI 53214
A Milwaukee Biopharmaceutical Company